Park Ha Biological Technology Co., Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Xiaoqiu Zhang
- Full Time Employees
- 17
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Address
- 901 & 901-2 Wuxi People's Republic of China 214000
- IPO Date
- Jan 19, 2005
- CIK
- 0001986247
- Website
- parkha.cn
- Similar Companies
- Business
- Park Ha Biological Technology Co., Ltd. (PHH) is a Cayman Islands holding company primarily engaged in developing proprietary skincare products under the Park Ha brand; direct sales through company-operated stores; franchise alliances under Park Ha and Geni store names; and value-added light beauty experience services, a complimentary after-sales treatment demonstrating product efficacy in stores across China. Founded in 2016 and headquartered in Wuxi, Jiangsu Province, China, the company operates via subsidiaries including Jiangsu Park Ha Biological Technology Co., Ltd. for R&D and stores, Shanghai Park Ha Industrial Development Co., Ltd. for franchisee training, and Wuxi Xinzhan Enterprise Management Consulting Co., Ltd. for marketing and franchising; it serves primarily women seeking cost-effective skin solutions through nearly 128 products in 14 series covering basic physical protection, exfoliation, sebum film repair, microecological balance, and anti-aging categories, with star offerings such as the Little Blue Injection Serum for hydration, brightening and firming via multiple peptides, and freeze-dried powders featuring fibronectin and cherry blossom extract for firmer skin, produced via third-party manufacturers under strict quality controls and collaborations with institutions like Jiangnan University. As of April 30, 2024, it maintains two directly operated stores and 43 franchisees in China, predominantly under Park Ha; recent developments include a December 2024 Nasdaq initial public offering raising $4.8 million to fund directly-owned store expansion, proprietary product patent acquisitions, and ingredient supplier purchases for cost reduction, alongside 2025 announcements for an annual general meeting proposing share capital increases, dual-class share structure adoption, share consolidation, and auditor appointment, plus reported pharmaceutical R&D advancements and clinical trial progress driving stock gains.
Company News
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
PHH, BYAH Investors Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
ROSEN, A LONGSTANDING FIRM, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
PHH, BYAH Investors Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
PHH, BYAH Investors Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit
ROSEN, LEADING TRIAL COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
ROSEN, RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
PHH, BYAH Investors Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH